U.S. Markets open in 6 hrs 44 mins
  • S&P Futures

    3,600.75
    +24.75 (+0.69%)
     
  • Dow Futures

    29,786.00
    +240.00 (+0.81%)
     
  • Nasdaq Futures

    11,966.75
    +61.50 (+0.52%)
     
  • Russell 2000 Futures

    1,837.40
    +20.30 (+1.12%)
     
  • Crude Oil

    43.50
    +0.44 (+1.02%)
     
  • Gold

    1,826.20
    -11.60 (-0.63%)
     
  • Silver

    23.45
    -0.18 (-0.77%)
     
  • EUR/USD

    1.1855
    +0.0010 (+0.0830%)
     
  • 10-Yr Bond

    0.8570
    0.0000 (0.00%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3343
    +0.0021 (+0.1561%)
     
  • USD/JPY

    104.4300
    -0.0580 (-0.0555%)
     
  • BTC-USD

    18,372.75
    +40.24 (+0.22%)
     
  • CMC Crypto 200

    368.28
    +6.85 (+1.90%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recap: Intra-Cellular Therapies Q2 Earnings

Benzinga Insights
·1 min read

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).

Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

View more earnings on ITCI

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/wen7vxux

Recent Stock Performance

52-week high: $43.56

52-week low: $6.75

Price action over last quarter: Up 7.13%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.